DrugPatentWatch Database Preview
TRIESENCE Drug Profile
» See Plans and Pricing
When do Triesence patents expire, and when can generic versions of Triesence launch?
Triesence is a drug marketed by Novartis and is included in one NDA. There are three patents protecting this drug.
This drug has twenty-five patent family members in twenty-one countries.
The generic ingredient in TRIESENCE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
US ANDA Litigation and Generic Entry Outlook for Triesence
A generic version of TRIESENCE was approved as triamcinolone acetonide by TARO on October 1st, 1986.
Summary for TRIESENCE
| International Patents: | 25 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 66 |
| Clinical Trials: | 5 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TRIESENCE |
| DailyMed Link: | TRIESENCE at DailyMed |
Recent Clinical Trials for TRIESENCE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Wake Forest University Health Sciences | Phase 4 |
| JHSPH Center for Clinical Trials | Phase 4 |
| National Eye Institute (NEI) | Phase 4 |
Pharmacology for TRIESENCE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for TRIESENCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Novartis | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Novartis | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRIESENCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TRIESENCE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2010141542 | Start Trial |
| Denmark | 2262506 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2009114521 | Start Trial |
| Canada | 2717605 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
